Pfizer has finalized plans to acquire Metsera for $4.9 billion, strategically positioning itself in the booming weight loss drug market projected to reach $100 billion by 2030. This acquisition follows Pfizer's earlier consideration of Viking Therapeutics, whose VK2735 drug demonstrates significant weight loss potential but faces safety and dropout concerns. The competitive landscape is dominated by Eli Lilly and Novo Nordisk, both of which successfully capitalize on the high demand for obesity treatments as they generate substantial revenues from their existing products.
“Viking Therapeutics VKTX · is developing · VK2735 · an investigational novel dual GLP-1 and GIP receptor agonist”
“Pfizer PFE · announced plans to acquire · Metsera · in a $4.9 billion deal”
“The transaction · is expected to be completed · before this year’s end · true”
“Pfizer · has massive R&D capabilities and deep pockets · Viking Therapeutics · could create pressure on”
“Patients on the highest drug dose of VK2735 · lost · up to 12.2% of their body weight · after 13 weeks of daily dosing”
“VK2735-treated patients · had dropout rates that were higher than expected · safety and tolerability questions · raised”
“Viking Therapeutics · could mitigate dropout issues · by using gradual dose escalation · true”
“The SC version of VK2735 · recently entered · late-stage development · true”
“Viking Therapeutics’ SC version of VK2735 · is likely their best shot at competing · Eli Lilly LLY and Novo Nordisk NVO · true”
“According to research conducted by Goldman Sachs · the obesity market in the United States · is expected to reach · $100 billion by 2030”
“Lilly and Novo · already generate a significant portion of · their topline from the sales of their respective obesity drugs · true”
“Amgen · initiated two phase III studies on · its investigational GIPR/GLP-1 RA drug, MariTide, in obesity · true”
.svg&width=160)